Appendix B

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Infliximab for ulcerative colitis

Final matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Schering-Plough Ltd (infliximab) Patient/carer groups • Continence Foundation • Colostomy Association • CORE (previously known as: Digestive Disorders Foundation) • InContact • National Association for Colitis and Crohn's Disease (NACC) • Ostomy Lifestyle Centre • Specialised Healthcare Alliance Professional groups • Association of Coloproctology of Great Britain and Ireland • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Society of Medicine – Intellectual Disabilities Forum Others • Department of Health • Luton Teaching PCT • Welsh Assembly Government	General • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium Comparator manufacturer(s) • Novartis Pharmaceuticals UK Ltd (ciclosporin) Relevant research groups • MRC Clinical Trials Unit Evidence Review Group • National Coordinating Centre for Health Technology Assessment • West Midlands Health Technology Assessment Collaboration Associated Guideline Groups • National Collaborating Centre for Nursing and Supportive Care

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.